NorthWest Biotherapeutics Inc (NWBO)

[abeta]

Alex

I did not read the article - it is "OUT THERE".
So I posted it.

Put me on ignore and move on.

The trial didn´t stop because for superior efficacy because of the unexpected high number of patients crossing over from placebo to dcvax-l. And because the primary endpoint was PFS, it was too hard to determine PFS/pseudo PFS. that´s the only reason.
So only the bullish case remains. Do your dd.